Concepts (311)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 22 | 2025 | 1147 | 2.330 |
Why?
|
| Liver Failure, Acute | 10 | 2025 | 98 | 2.010 |
Why?
|
| Hepatitis, Alcoholic | 4 | 2025 | 30 | 1.760 |
Why?
|
| Hypertension, Portal | 5 | 2017 | 78 | 1.400 |
Why?
|
| Acetaminophen | 7 | 2025 | 100 | 1.250 |
Why?
|
| Hepatic Encephalopathy | 14 | 2015 | 83 | 1.240 |
Why?
|
| Chemical and Drug Induced Liver Injury | 5 | 2024 | 157 | 1.210 |
Why?
|
| Extracorporeal Circulation | 9 | 2019 | 49 | 1.070 |
Why?
|
| Hypertension, Pulmonary | 5 | 2017 | 457 | 1.060 |
Why?
|
| Liver, Artificial | 4 | 2014 | 9 | 0.940 |
Why?
|
| Liver Failure | 6 | 2017 | 99 | 0.940 |
Why?
|
| Artificial Organs | 9 | 1996 | 11 | 0.940 |
Why?
|
| Drug Overdose | 5 | 2024 | 73 | 0.900 |
Why?
|
| Endpoint Determination | 1 | 2025 | 58 | 0.870 |
Why?
|
| Liver | 17 | 2025 | 1796 | 0.830 |
Why?
|
| Clinical Trials as Topic | 3 | 2025 | 1129 | 0.800 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2024 | 62 | 0.740 |
Why?
|
| Hepacivirus | 3 | 2018 | 273 | 0.700 |
Why?
|
| Hepatocytes | 4 | 2012 | 232 | 0.590 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2019 | 2 | 0.590 |
Why?
|
| Hepatitis C | 3 | 2018 | 381 | 0.570 |
Why?
|
| Analgesics | 1 | 2019 | 120 | 0.560 |
Why?
|
| Alcoholism | 2 | 2024 | 244 | 0.530 |
Why?
|
| Ammonia | 2 | 2015 | 67 | 0.460 |
Why?
|
| Lactulose | 1 | 2015 | 27 | 0.450 |
Why?
|
| Rifamycins | 1 | 2015 | 18 | 0.450 |
Why?
|
| Digestive System Neoplasms | 1 | 2015 | 12 | 0.440 |
Why?
|
| Gastrointestinal Agents | 1 | 2015 | 67 | 0.430 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2015 | 77 | 0.410 |
Why?
|
| Models, Statistical | 2 | 2017 | 483 | 0.410 |
Why?
|
| Hepatitis C, Chronic | 3 | 2016 | 356 | 0.400 |
Why?
|
| Disease Eradication | 1 | 2014 | 39 | 0.400 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 193 | 0.390 |
Why?
|
| Humans | 58 | 2025 | 131163 | 0.390 |
Why?
|
| Antiviral Agents | 3 | 2016 | 807 | 0.360 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2011 | 8 | 0.340 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 421 | 0.330 |
Why?
|
| Models, Biological | 2 | 2013 | 1371 | 0.330 |
Why?
|
| Citrullinemia | 1 | 2010 | 16 | 0.320 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2023 | 53 | 0.320 |
Why?
|
| 5-Aminolevulinate Synthetase | 1 | 2008 | 2 | 0.290 |
Why?
|
| Iron Overload | 1 | 2008 | 18 | 0.290 |
Why?
|
| Anemia, Sideroblastic | 1 | 2008 | 15 | 0.290 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2008 | 81 | 0.270 |
Why?
|
| Cation Transport Proteins | 1 | 2008 | 100 | 0.270 |
Why?
|
| Tissue Donors | 4 | 2025 | 506 | 0.270 |
Why?
|
| Biomedical Research | 1 | 2014 | 561 | 0.270 |
Why?
|
| Antihypertensive Agents | 2 | 2011 | 414 | 0.260 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2007 | 6 | 0.260 |
Why?
|
| Vasodilator Agents | 3 | 2014 | 197 | 0.250 |
Why?
|
| Liver Cirrhosis | 2 | 2011 | 903 | 0.250 |
Why?
|
| Ascites | 1 | 2007 | 99 | 0.250 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2004 | 149 | 0.240 |
Why?
|
| Epoprostenol | 1 | 2006 | 33 | 0.240 |
Why?
|
| Hepatitis E | 1 | 2006 | 6 | 0.240 |
Why?
|
| Sitosterols | 1 | 2025 | 10 | 0.220 |
Why?
|
| Travel | 1 | 2006 | 117 | 0.220 |
Why?
|
| Liver Diseases | 3 | 2018 | 385 | 0.220 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 293 | 0.220 |
Why?
|
| Treatment Outcome | 10 | 2025 | 12936 | 0.210 |
Why?
|
| Abdominal Pain | 1 | 2007 | 319 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 294 | 0.210 |
Why?
|
| Mutation, Missense | 1 | 2008 | 919 | 0.210 |
Why?
|
| Research Design | 2 | 2025 | 716 | 0.200 |
Why?
|
| Drug Design | 1 | 2004 | 156 | 0.190 |
Why?
|
| Adult | 17 | 2025 | 31282 | 0.190 |
Why?
|
| Pulmonary Artery | 3 | 2017 | 434 | 0.180 |
Why?
|
| Middle Aged | 16 | 2025 | 28601 | 0.180 |
Why?
|
| Administration, Oral | 2 | 2014 | 711 | 0.170 |
Why?
|
| Alcohol Drinking | 1 | 2024 | 341 | 0.170 |
Why?
|
| Patient Selection | 1 | 2025 | 729 | 0.170 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2000 | 47 | 0.160 |
Why?
|
| Brain Diseases | 1 | 2023 | 299 | 0.160 |
Why?
|
| Male | 23 | 2025 | 64957 | 0.160 |
Why?
|
| Professional Practice Location | 1 | 2019 | 8 | 0.150 |
Why?
|
| Alkaline Phosphatase | 3 | 1989 | 93 | 0.150 |
Why?
|
| Gastroenterologists | 1 | 2019 | 14 | 0.150 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2019 | 38 | 0.140 |
Why?
|
| Needs Assessment | 1 | 2019 | 173 | 0.140 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 3061 | 0.140 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2018 | 44 | 0.140 |
Why?
|
| Renal Dialysis | 3 | 1996 | 951 | 0.130 |
Why?
|
| Donor Selection | 1 | 2018 | 60 | 0.130 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2024 | 78 | 0.130 |
Why?
|
| Alanine Transaminase | 3 | 2013 | 153 | 0.130 |
Why?
|
| Hemodynamics | 2 | 2012 | 810 | 0.130 |
Why?
|
| Arterial Pressure | 2 | 2017 | 131 | 0.130 |
Why?
|
| Female | 19 | 2025 | 70963 | 0.130 |
Why?
|
| Tissue and Organ Procurement | 2 | 2017 | 254 | 0.130 |
Why?
|
| Narcotics | 1 | 2017 | 61 | 0.130 |
Why?
|
| Transplant Recipients | 1 | 2019 | 235 | 0.120 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 2304 | 0.120 |
Why?
|
| Graft Survival | 2 | 2019 | 465 | 0.120 |
Why?
|
| Immunoassay | 1 | 2016 | 126 | 0.120 |
Why?
|
| Sofosbuvir | 1 | 2016 | 20 | 0.120 |
Why?
|
| Headache | 1 | 2016 | 107 | 0.120 |
Why?
|
| Retrospective Studies | 9 | 2025 | 17753 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 555 | 0.120 |
Why?
|
| Time Factors | 4 | 2019 | 6196 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 2 | 2013 | 80 | 0.110 |
Why?
|
| Ornithine | 1 | 2015 | 31 | 0.110 |
Why?
|
| Liver Regeneration | 4 | 1996 | 39 | 0.110 |
Why?
|
| Waiting Lists | 1 | 2017 | 253 | 0.110 |
Why?
|
| Dogs | 5 | 1994 | 613 | 0.110 |
Why?
|
| Glycerol | 1 | 2015 | 78 | 0.110 |
Why?
|
| Gallbladder Neoplasms | 1 | 2015 | 15 | 0.110 |
Why?
|
| Dipeptides | 1 | 2015 | 60 | 0.110 |
Why?
|
| Phenylbutyrates | 1 | 2015 | 54 | 0.110 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2015 | 75 | 0.110 |
Why?
|
| Graft Rejection | 1 | 2019 | 552 | 0.110 |
Why?
|
| Arteriovenous Fistula | 1 | 2015 | 54 | 0.110 |
Why?
|
| Blood Pressure | 3 | 2012 | 1345 | 0.110 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2015 | 103 | 0.110 |
Why?
|
| United States | 7 | 2023 | 12072 | 0.100 |
Why?
|
| Liver Function Tests | 2 | 2010 | 97 | 0.100 |
Why?
|
| Hepatitis | 1 | 1994 | 56 | 0.100 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 193 | 0.100 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2013 | 3 | 0.100 |
Why?
|
| Prognosis | 5 | 2023 | 4886 | 0.100 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 173 | 0.100 |
Why?
|
| Assisted Circulation | 1 | 1993 | 23 | 0.100 |
Why?
|
| Cholangiocarcinoma | 1 | 2015 | 126 | 0.100 |
Why?
|
| Bile Duct Neoplasms | 1 | 2015 | 130 | 0.100 |
Why?
|
| Malnutrition | 1 | 2015 | 163 | 0.100 |
Why?
|
| Animals | 14 | 2019 | 33912 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1295 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 789 | 0.090 |
Why?
|
| Mass Screening | 1 | 2018 | 822 | 0.090 |
Why?
|
| Schistosomiasis mansoni | 1 | 2012 | 24 | 0.090 |
Why?
|
| Probiotics | 1 | 2015 | 227 | 0.090 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 44 | 0.090 |
Why?
|
| Length of Stay | 1 | 2017 | 1421 | 0.090 |
Why?
|
| Blood Proteins | 1 | 1992 | 143 | 0.090 |
Why?
|
| Registries | 3 | 2025 | 1634 | 0.090 |
Why?
|
| Hepatectomy | 1 | 1992 | 131 | 0.080 |
Why?
|
| Allografts | 2 | 2025 | 220 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 292 | 0.080 |
Why?
|
| Argininosuccinate Synthase | 1 | 2010 | 25 | 0.080 |
Why?
|
| Risk Factors | 5 | 2019 | 11074 | 0.080 |
Why?
|
| Fibrosis | 1 | 2012 | 429 | 0.080 |
Why?
|
| Creatinine | 1 | 2012 | 398 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 1173 | 0.080 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2010 | 36 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1882 | 0.080 |
Why?
|
| Aged | 9 | 2025 | 21025 | 0.080 |
Why?
|
| Cell Line | 4 | 2000 | 2552 | 0.080 |
Why?
|
| Diet, Protein-Restricted | 1 | 2010 | 71 | 0.080 |
Why?
|
| Gastroenterology | 1 | 2012 | 233 | 0.070 |
Why?
|
| Citrulline | 1 | 2010 | 128 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 621 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 4066 | 0.070 |
Why?
|
| Young Adult | 5 | 2025 | 10103 | 0.070 |
Why?
|
| Hospitalization | 1 | 2017 | 1950 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 775 | 0.070 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 108 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2010 | 825 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 405 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 2085 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2018 | 6459 | 0.060 |
Why?
|
| Veterans | 1 | 2018 | 1763 | 0.060 |
Why?
|
| Computer Simulation | 2 | 2013 | 674 | 0.060 |
Why?
|
| Recurrence | 1 | 2010 | 1489 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 345 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 982 | 0.060 |
Why?
|
| Jaundice | 1 | 2006 | 27 | 0.060 |
Why?
|
| Cause of Death | 2 | 2019 | 506 | 0.060 |
Why?
|
| Isoenzymes | 1 | 1986 | 211 | 0.060 |
Why?
|
| India | 1 | 2006 | 234 | 0.060 |
Why?
|
| Intestines | 1 | 1989 | 587 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2018 | 497 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 531 | 0.050 |
Why?
|
| Necrosis | 1 | 2025 | 192 | 0.050 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2004 | 14 | 0.050 |
Why?
|
| Toxicology | 1 | 2004 | 8 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2019 | 3711 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 1373 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2004 | 59 | 0.050 |
Why?
|
| Intestine, Small | 1 | 1986 | 291 | 0.050 |
Why?
|
| Cysteine | 1 | 2024 | 137 | 0.050 |
Why?
|
| Biological Assay | 1 | 2004 | 105 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2006 | 358 | 0.050 |
Why?
|
| Caspases | 1 | 2004 | 152 | 0.050 |
Why?
|
| Cardiomyopathies | 1 | 2008 | 514 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2004 | 315 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 265 | 0.050 |
Why?
|
| alpha-Fetoproteins | 2 | 1994 | 125 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2009 | 2885 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2008 | 668 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2006 | 824 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 1986 | 569 | 0.050 |
Why?
|
| Serum Albumin | 2 | 1994 | 101 | 0.050 |
Why?
|
| North America | 1 | 2023 | 255 | 0.050 |
Why?
|
| Coma | 1 | 2023 | 56 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2018 | 1240 | 0.050 |
Why?
|
| RNA | 1 | 1986 | 517 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2025 | 314 | 0.050 |
Why?
|
| Equipment Design | 2 | 1994 | 512 | 0.050 |
Why?
|
| Bilirubin | 1 | 2023 | 126 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 512 | 0.040 |
Why?
|
| Ischemia | 1 | 2024 | 359 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2025 | 1626 | 0.040 |
Why?
|
| Biomarkers | 1 | 2010 | 3385 | 0.040 |
Why?
|
| Cytochrome P-450 CYP1A2 Inhibitors | 1 | 2000 | 3 | 0.040 |
Why?
|
| Theophylline | 1 | 2000 | 23 | 0.040 |
Why?
|
| Methylcholanthrene | 1 | 2000 | 18 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 2000 | 92 | 0.040 |
Why?
|
| Fluorescence | 1 | 2000 | 94 | 0.040 |
Why?
|
| Oxazines | 1 | 2000 | 33 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 1994 | 975 | 0.040 |
Why?
|
| Vascular Resistance | 2 | 2017 | 182 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5196 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 33 | 0.040 |
Why?
|
| Hepatitis Viruses | 1 | 2018 | 2 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 267 | 0.030 |
Why?
|
| Portal Pressure | 1 | 2017 | 3 | 0.030 |
Why?
|
| Pregnancy | 1 | 2010 | 7512 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 573 | 0.030 |
Why?
|
| Metagenomics | 1 | 2018 | 116 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2004 | 2465 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2018 | 448 | 0.030 |
Why?
|
| Pulmonary Circulation | 1 | 2017 | 113 | 0.030 |
Why?
|
| Mutation | 1 | 2010 | 6099 | 0.030 |
Why?
|
| Jejunum | 2 | 1988 | 123 | 0.030 |
Why?
|
| Adolescent | 4 | 2018 | 20987 | 0.030 |
Why?
|
| Oxygen Consumption | 2 | 1996 | 294 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 1996 | 62 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2016 | 46 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 563 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1356 | 0.030 |
Why?
|
| Rats | 4 | 1989 | 3370 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 1996 | 145 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2018 | 564 | 0.030 |
Why?
|
| Sorption Detoxification | 1 | 1994 | 1 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1994 | 73 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1071 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 729 | 0.030 |
Why?
|
| Survival Rate | 2 | 1996 | 2114 | 0.030 |
Why?
|
| Galactose | 1 | 1994 | 53 | 0.030 |
Why?
|
| Giant Cells | 1 | 1994 | 33 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 416 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1378 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 526 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1410 | 0.020 |
Why?
|
| Pilot Projects | 2 | 1996 | 1445 | 0.020 |
Why?
|
| Life Support Systems | 1 | 1993 | 5 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 1994 | 158 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 889 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1993 | 305 | 0.020 |
Why?
|
| Transferrin | 1 | 1992 | 46 | 0.020 |
Why?
|
| Rats, Inbred Strains | 3 | 1988 | 181 | 0.020 |
Why?
|
| Age Factors | 1 | 2019 | 2825 | 0.020 |
Why?
|
| Methionine Sulfoximine | 1 | 1992 | 1 | 0.020 |
Why?
|
| Buthionine Sulfoximine | 1 | 1992 | 9 | 0.020 |
Why?
|
| Methemoglobinemia | 1 | 1992 | 9 | 0.020 |
Why?
|
| Vacuoles | 1 | 1992 | 28 | 0.020 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1992 | 81 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2904 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 1992 | 54 | 0.020 |
Why?
|
| Algorithms | 1 | 2018 | 1680 | 0.020 |
Why?
|
| Critical Care | 1 | 1996 | 686 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3829 | 0.020 |
Why?
|
| Phosphatidylinositol Diacylglycerol-Lyase | 1 | 1989 | 1 | 0.020 |
Why?
|
| Isoelectric Focusing | 1 | 1989 | 22 | 0.020 |
Why?
|
| Monensin | 1 | 1989 | 7 | 0.020 |
Why?
|
| Butyric Acid | 1 | 1989 | 7 | 0.020 |
Why?
|
| Phospholipase D | 1 | 1989 | 8 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 1992 | 643 | 0.020 |
Why?
|
| Microvilli | 1 | 1989 | 61 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 1989 | 62 | 0.020 |
Why?
|
| Butyrates | 1 | 1989 | 39 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1989 | 89 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 254 | 0.020 |
Why?
|
| Ileum | 1 | 1989 | 109 | 0.020 |
Why?
|
| Duodenum | 1 | 1989 | 111 | 0.020 |
Why?
|
| Apoproteins | 1 | 1988 | 11 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 1988 | 49 | 0.020 |
Why?
|
| Biopsy | 1 | 1992 | 1239 | 0.020 |
Why?
|
| Blood Glucose | 1 | 1992 | 1117 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6797 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1988 | 278 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1989 | 262 | 0.020 |
Why?
|
| Common Bile Duct | 1 | 1986 | 16 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 1986 | 10 | 0.020 |
Why?
|
| Cell-Free System | 1 | 1986 | 62 | 0.010 |
Why?
|
| Contraindications | 1 | 2006 | 75 | 0.010 |
Why?
|
| Microsomes | 1 | 1986 | 35 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 1986 | 54 | 0.010 |
Why?
|
| Ribavirin | 1 | 2006 | 85 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 235 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2006 | 238 | 0.010 |
Why?
|
| Child | 2 | 1994 | 26341 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 1319 | 0.010 |
Why?
|
| Peptides | 1 | 1986 | 708 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1986 | 2395 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1989 | 972 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1989 | 1928 | 0.010 |
Why?
|
| Factor V | 1 | 1996 | 15 | 0.010 |
Why?
|
| Platelet Count | 1 | 1996 | 139 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1996 | 153 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1996 | 170 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1988 | 2550 | 0.010 |
Why?
|
| Apolipoproteins A | 1 | 1988 | 51 | 0.000 |
Why?
|
| Apolipoprotein A-I | 1 | 1988 | 80 | 0.000 |
Why?
|
| Organ Culture Techniques | 1 | 1988 | 140 | 0.000 |
Why?
|
| Apolipoproteins E | 1 | 1988 | 187 | 0.000 |
Why?
|
| Immune Sera | 1 | 1986 | 54 | 0.000 |
Why?
|
| Ligation | 1 | 1986 | 134 | 0.000 |
Why?
|
| Triglycerides | 1 | 1988 | 602 | 0.000 |
Why?
|
| Cholesterol | 1 | 1988 | 539 | 0.000 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1986 | 359 | 0.000 |
Why?
|
| Placenta | 1 | 1986 | 504 | 0.000 |
Why?
|